This “Italy Healthcare Outlook 2022” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in Italy. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of Italy.
As per the analysis, National Committees have reduced income inequality, giving stipends to the poor, shrinking the gap between high and low incomes, raising pensions and minimum wages as they're high enough to live on, and fixed tax structure eventually leads to good healthcare system. The Government health care make sure everyone has access to affordable healthcare, gives working staffs the same freedom to have kids (maternity leave), convalesce (sick leave), and relax (proper vacations). R&D pharma investments in Italy are growing rapidly. Italy and the UK, provide universal access to treatment and medications, with minimal point-of-service payments and with prices kept down by government negotiation represents good governance.
Italy officially the Italian Republic, with 60.36 million people, distributed on a territory of 301,338 square kilometers. Italy is the 4th country in the world healthcare ranking. Italy's healthcare system is routinely ranked among the best in the world, based on its overall quality, equity of access, and the general health and life expectancy of the Italian population. In 2019, GDP growth for Italy was 0.30%. The healthcare system in Italy is a regionally based national health service known as Servizio Sanitario Nazionale (SSN). It provides universal coverage to citizens and residents, with public healthcare largely free of charge. Public Health Service in Italy covers both citizens and legal nationals of foreign countries. It is financed by corporate and value-added tax revenues rose by the central government and allocated to the caregiving state governments.
Private health insurance plays a small part in the health care system in Italy. The central government is responsible for national health goals and objectives. Also the central government decides annual SSN funding and monitors resource allocation for each region. Patients make prescription costs for hospital appointments and operations as well as for certain ambulatory medications. Expectant women, HIV patients or other medical conditions, and young children and older adults in lower-income households are excluded from cost sharing. Even if an individual venture outside the National Health Service to private doctors and hospitals, Italian healthcare is far less expensive. In terms of healthcare, child mortality, obesity, cancer, diabetes, suicide, drug addiction, suicides, and disability rates, the Italians are much healthier than the Americans. As Italy is being adversely affected by COVID-19, on March 16th 2020, the Italian Government presented a 25-billion-euro package as an immediate response to the COVID-19 outbreak in order to strengthen the Italian health care system and support companies, workers, and families. The aim is to protect citizens' health, support businesses, and preserve employment levels and incomes.
Italy is the leading producer of pharmaceuticals in the European Union. With $35 billion the value of production exceeds that of Germany and the other major EU countries. Pharmaceutical export in Italy has grown more than big European countries average. The performance of export is the result of an increased quality of medicines and vaccines exported all over the world.
Italy is a hub for clinical trials, due to the scientific expertise, excellences in industry, universities and NHS structures Use of medicines and vaccines has made a major contribution to health in Italy and other countries, but in Italy the pharmaceutical spending is lower compared to other economies. Italy is the world leading country for the number of innovative contracts between companies and the NHS.
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in Italy.
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in Italy.
Market access section of the Italy Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The services that the National Health System is expected to deliver to all the citizens, free of charge at the point of access or upon payment of a small pro capita charge. The ELHC costs are covered by public resources that are collected from the general taxation yield. It can be divided in three large groups: collective health care in the life and working environments, district health care, including the health and social care services, hospital care, in emergency wards, ordinary hospitalization. The Italian National Health Service is structured on three main different levels (central, regional and local).
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
As per the analysis, National Committees have reduced income inequality, giving stipends to the poor, shrinking the gap between high and low incomes, raising pensions and minimum wages as they're high enough to live on, and fixed tax structure eventually leads to good healthcare system. The Government health care make sure everyone has access to affordable healthcare, gives working staffs the same freedom to have kids (maternity leave), convalesce (sick leave), and relax (proper vacations). R&D pharma investments in Italy are growing rapidly. Italy and the UK, provide universal access to treatment and medications, with minimal point-of-service payments and with prices kept down by government negotiation represents good governance.
Italy Healthcare Outlook
Italy officially the Italian Republic, with 60.36 million people, distributed on a territory of 301,338 square kilometers. Italy is the 4th country in the world healthcare ranking. Italy's healthcare system is routinely ranked among the best in the world, based on its overall quality, equity of access, and the general health and life expectancy of the Italian population. In 2019, GDP growth for Italy was 0.30%. The healthcare system in Italy is a regionally based national health service known as Servizio Sanitario Nazionale (SSN). It provides universal coverage to citizens and residents, with public healthcare largely free of charge. Public Health Service in Italy covers both citizens and legal nationals of foreign countries. It is financed by corporate and value-added tax revenues rose by the central government and allocated to the caregiving state governments.
Private health insurance plays a small part in the health care system in Italy. The central government is responsible for national health goals and objectives. Also the central government decides annual SSN funding and monitors resource allocation for each region. Patients make prescription costs for hospital appointments and operations as well as for certain ambulatory medications. Expectant women, HIV patients or other medical conditions, and young children and older adults in lower-income households are excluded from cost sharing. Even if an individual venture outside the National Health Service to private doctors and hospitals, Italian healthcare is far less expensive. In terms of healthcare, child mortality, obesity, cancer, diabetes, suicide, drug addiction, suicides, and disability rates, the Italians are much healthier than the Americans. As Italy is being adversely affected by COVID-19, on March 16th 2020, the Italian Government presented a 25-billion-euro package as an immediate response to the COVID-19 outbreak in order to strengthen the Italian health care system and support companies, workers, and families. The aim is to protect citizens' health, support businesses, and preserve employment levels and incomes.
Italy Industry Overview Chapter
Pharmaceutical
Italy is the leading producer of pharmaceuticals in the European Union. With $35 billion the value of production exceeds that of Germany and the other major EU countries. Pharmaceutical export in Italy has grown more than big European countries average. The performance of export is the result of an increased quality of medicines and vaccines exported all over the world.
Medical Device
Italy is a hub for clinical trials, due to the scientific expertise, excellences in industry, universities and NHS structures Use of medicines and vaccines has made a major contribution to health in Italy and other countries, but in Italy the pharmaceutical spending is lower compared to other economies. Italy is the world leading country for the number of innovative contracts between companies and the NHS.
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in Italy.
Italy Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in Italy.
Italy: Market Access
Market access section of the Italy Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The services that the National Health System is expected to deliver to all the citizens, free of charge at the point of access or upon payment of a small pro capita charge. The ELHC costs are covered by public resources that are collected from the general taxation yield. It can be divided in three large groups: collective health care in the life and working environments, district health care, including the health and social care services, hospital care, in emergency wards, ordinary hospitalization. The Italian National Health Service is structured on three main different levels (central, regional and local).
Italy: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
- Overview of the pharmaceutical and medical device markets
- An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market
Italy Report Insights
- Italy - Healthcare Outlook
- Italy - Healthcare Assessment
- Italy - Market Access
- Italy - Healthcare Market Perspectives
- Italy - Analyst Views
Key Questions Answered
- What are business strategies and trends shaping and driving the Italy healthcare market?
- What are reimbursement and regulatory policies, pharmaceutical and medical device market segments and companies likely to impact the Italy healthcare market in the future?
- How to organize sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment and strategic partnership?
- How to identify, understand and capitalize on the opportunities and challenges in the Italy healthcare market?
Key Players
- Health Italia S.p.A.
- Claire SpA
- Isomed Implant Systems
- Medico SpA
- BMG Pharma
- Termoletto Italiana Srl
- World Work Srl
Table of Contents
1. Key Insights2. Italy at a Glance
3. Executive Summary
3.1. Overview
3.2. Key Reforms in Italy Healthcare Market
3.3. Healthcare Facility Administrative Structure
3.4. Governmental Healthcare Policy
3.5. Industry Overview
3.5.1. Pharmaceutical
3.5.1.1. Supply Channels
3.5.1.2. Major Players
3.5.1.3. Prescription VS OTC Drugs
3.5.2. Medical Device
3.5.2.1. Supply Chain
3.5.2.2. Major Distributors
3.6. Strategic Location
3.7. COVID-19 Update
3.8. Healthcare Technology Update
4. Assessment
4.1. Healthcare
4.1.1. Healthcare Facilities (Beds, Hospitals and Pharmacy)
4.1.2. Life Expectancy and Immunization Rate
4.1.3. Environmental Health (PM2.5 and CO2)
4.1.4. Healthcare Workforce (Physicians, Dentists and Nurses)
4.1.5. Healthcare Expenditure as share of GDP
4.1.6. Healthcare Expenditure
4.1.7. Out of Pocket Expenditure as share of current health expenditure
4.1.8. Pharmaceutical Imports and Exports
4.2. Economic
4.2.1. Gross Domestic Product
4.2.2. Inflation
4.2.3. Unemployment
4.2.4. Trade Association, Italy
4.2.5. Trade Fairs, Italy
5. Market Access
5.1. Overview of Healthcare System Regulatory Bodies, Italy
5.2. Reimbursement Process, Italy
5.3. Health Insurance, Italy
5.4. Pricing Policies, Italy
5.5. Regulatory Landscape, Italy
5.5.1. Market Authorization for Pharmaceutical Products, Italy
5.5.2. Market Authorization for Medical Devices, Italy
5.5.3. Licensing Process for Pharmaceutical and Medical Device Manufacturing, Italy
5.5.4. Licensing Process for Pharmaceutical Exports and Imports, Italy
5.5.5. Intellectual Property Rights, Italy
5.5.5.1. Patent
5.5.5.2. Trademark
5.5.6. Clinical Trial Regulations, Italy
5.5.6.1. Pharmaceutical Clinical Trials Landscape, Italy
5.5.6.2. Medical Device Clinical Trials Landscape, Italy
5.5.7. Pharmaceutical Advertising Regulations, Italy
5.5.8. Medical Device Advertising Regulations, Italy
5.5.9. Pharmacy Regulations, Italy
5.5.10. Labeling and Packaging Regulations, Italy
6. Italy PESTLE Analysis
7. Driver and Barriers
8. Appendix
8.1. Research Methodology
8.1.1. Coverage
8.1.2. Secondary Research
9. References
10. Publisher Capabilities
11. Disclaimer
12. About the PublisherList of Tables
Table 1 Pharmaceutical Market, Italy, Exports and Imports ($m)
Table 7 Market Access, Italy, Health Insurance Population Coverage (%)
Table 12 Market Access, Italy, Out-of-Pocket Expenditure (%)
Table 19 Regulatory Landscape, Italy, Labeling Guidelines
Table 23 Demographics, Italy, Immunization Rate (%)
Table 28 Demographics, Italy, Life Expectancy at Birth (years)
Table 32 Healthcare Infrastructure, Italy, Doctors (per 1,000 population)
Table 36 Healthcare Infrastructure, Italy, CO2 Emissions (metric tons per capita)
Table 40 Healthcare Infrastructure, Italy, Nurses (per 1,000 population)
Table 42 Healthcare Expenditure, Italy, Major Healthcare Trade Fairs
List of Figures
Figure 1 Pharmaceutical Market, Italy, Supply Chain
Figure 4 Market Access, Italy, Overview of Healthcare System
Figure 7 Market Access, Italy, Marketing Authorization Procedure
Figure 9 Market Access, Italy, Patent Approval Process
Figure 11 Demographics, Italy, Immunization Rate (%)
Figure 15 Healthcare Expenditure, Italy, Healthcare Expenditure (% of GDP)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Health Italia S.p.A.
- Claire SpA
- Isomed Implant Systems
- Medico SpA
- BMG Pharma
- Termoletto Italiana Srl
- World Work Srl
